Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03582475
Title	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Jonsson Comprehensive Cancer Center
Indications	prostate neuroendocrine neoplasm urethra cancer prostate small cell carcinoma ureter small cell carcinoma urinary bladder small cell neuroendocrine carcinoma
Therapies	Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA